[Clinical studies on cefozopran in pediatrics]

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology
• Bacteriology

Background:

• Pediatric bacterial infections pose significant health risks.
• Effective antibiotic treatment is crucial for favorable outcomes.
• Cefozopran (CZOP) is a third-generation cephalosporin with broad-spectrum activity.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of Cefozopran (CZOP) in pediatric patients.
• To assess the bacteriological eradication rates of pathogens in children treated with CZOP.
• To determine the incidence of adverse events associated with CZOP administration in pediatric populations.

Main Methods:

• Intravenous administration of Cefozopran (CZOP) to 9 pediatric patients (1 month to 13 years).
• Dose range: 56.7–200 mg/kg/day, divided into 3 or 4 doses.
• Clinical and bacteriological assessments were performed on patients with various bacterial infections.

Main Results:

• Overall clinical efficacy rate of 100% (6 excellent, 2 good) in 8 evaluated patients.
• Bacteriological eradication of all 5 pathogen strains (Haemophilus influenzae, Staphylococcus aureus, Escherichia coli).
• Adverse events observed in 4 cases: wheal (1), elevated GOT/GPT (2), eosinophilia (1).

Conclusions:

• Cefozopran (CZOP) is highly effective for treating pediatric bacterial infections.
• The drug demonstrated excellent bacteriological eradication of common pediatric pathogens.
• CZOP appears to be a safe and effective therapeutic option for children with bacterial infections.